Statistics
Publications
44
Citations
3.7K
H-Index
28
Active since
1982
Thomas F. Bumol is an author at Eli Lilly (United States) specializing in life sciences, oncology, and pharmacology.
Publications per year
1982–2025
44
44
The Effects of LY2405319, an FGF21 Analog, in Obese Human Subjects with Type 2 Diabetes
Gregory Gaich, Jenny Y. Chien, Haoda Fu et al. · Cell Metabolism · 2013 · 879 citations · Full text
Rational Design of a Fibroblast Growth Factor 21-Based Clinical Candidate, LY2405319
Alexei Kharitonenkov, John M. Beals, Radmila Micanovic et al. · PLoS ONE · 2013 · 165 citations · Full text
Pharmacy, Biochemistry, Pharmacology +17
1–5 of 44